Mississippi, South Carolina and Alabama bar licensees from research grade peptides, waivers or not
Mississippi, South Carolina and Alabama have issued near identical notices: no licensee may compound, prescribe, administer or dispense a research grade peptide, patient waivers do nothing, and every drug or ingredient must come from a board permitted pharmacy.
On August 19, 2026 Mississippi's boards of pharmacy, medical licensure and nursing issued a joint statement: under no circumstances may a provider compound, administer, prescribe or dispense a non FDA approved or research grade peptide, delegation is no workaround, and all prescription products and ingredients must come from an entity permitted by the Mississippi Board of Pharmacy. Unlicensed shippers can be reported.
South Carolina's Board of Medical Examiners published the same position, naming semaglutide, stating that any facility inside or outside South Carolina selling drugs into the state without a South Carolina pharmacy permit is acting unlawfully, and warning that buying from an unpermitted facility is aiding unlicensed practice. Alabama's board published matching language earlier in the year.
- Licensees in the three states.
- Compounders and online sellers shipping peptides into them, permitted or not.
- Telehealth and wellness programs offering peptides to their residents.
Board notices restate existing law for licensees in each state. Their reach to out of state sellers comes through the permit requirement: each state says drugs and ingredients must come from an entity permitted by its board of pharmacy.
| Source published | August 19, 2026 | Mississippi joint statement. The South Carolina and Alabama notices carry no date on their face. |
|---|
While FDA's bulk substance process moves slowly, states are settling the question for their own licensees: no research grade product, and only permitted sources. For a shipping pharmacy that turns a nonresident permit into a market access requirement, and the shared wording means more states will follow.
- Check your nonresident permits in Mississippi, South Carolina and Alabama and stop shipping peptides where you hold none.
- Remove research grade or research use only products from any catalog reaching those states.
- Retire any patient waiver that describes a product as research grade.
Compounding (503A and 503B). The Compounding domain covers the substances a pharmacy compounds and where they come from; the Licensure and Registration domain covers the state permits a shipping pharmacy needs. These notices tie the two together for peptides.
- Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides PrimaryMississippi Board of Nursing, Mississippi Board of Pharmacy, Mississippi State Board of Medical LicensureRetrieved Sep 21, 2026
Signed statement dated 8/19/2026; prohibition, permitted source requirement, consent form paragraph.
- Peptide Statement SecondaryMississippi State Board of Medical LicensureRetrieved Sep 21, 2026
- Notice Concerning the Prescribing of Research-Grade Peptides and FDA-Ineligible Peptides PrimarySouth Carolina Board of Medical ExaminersRetrieved Sep 21, 2026
Semaglutide named; facilities within or outside South Carolina; S.C. Code sections 40-43-83 and 40-43-89; footnote 1 on Category 2 peptides; aiding and abetting paragraph.
- Board Issues Official Notice Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides PrimaryAlabama Board of Medical Examiners and Medical Licensure CommissionRetrieved Sep 21, 2026
Prohibition, permitted source requirement and consent form paragraph. The page carries no publication date.
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.